Tamgiblimab
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) . Tamgiblimab has anticancer effects[1].
Product Specifications
CAS Number
[2411914-36-6]
Product Name Alternative
IBI939
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tamgiblimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Tamgiblimab]
Molecular Weight
(144.34 kDa)
References & Citations
[1]Y. Cheng, et al. 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) . Immuno-Oncology and Technology. DECEMBER 01, 2022.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1071026-01 0.05 mg (E-Coli)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details MBS1071026-02 0.05 mg (Baculovirus)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details 
MBS1071026-03 0.2 mg (E-Coli)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details 
MBS1071026-04 0.2 mg (Yeast)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details MBS1071026-05 0.5 mg (E-Coli)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details MBS1071026-06 0.05 mg (Mammalian-Cell)
Recombinant Campylobacter jejuni subsp.jejuni serotype O:2 Lysine--tRNA ligase (lysS), partial
Ask
View Details